Search Results for:
-
Cempra Adds $50.8M to Push Pivotal Solithromycin Program
Cempra execs couldn't comment on the news, but President and CEO Prabhavathi Fernandes said during a presentation at the Jefferies Global Health Care Conference earlier this month that the I.V.-to-oral stepdown study was expected to start in the fourth quarter of this year...treatment often end up staying in the hospital for seven to 10 days to complete treatment, contributing to the increases in health care costsBy Jennifer Boggs | BioWorld Today | Monday, June 17, 2013 -
J&J Doing its Best VC Imitation With Incubators, Entrepreneurs
With the opening of its California Innovation Center based in Menlo Park earlier this month, the New Brunswick, N.J.-based company has established regional innovation centers, incubators, and entrepreneurs in residence to get J&J closer to early stage products that might be licensed or acquired by the health-care giantBy Brian Orelli | BioWorld Insight | Monday, June 17, 2013 -
'Tea'-ing Off in China? Celgene Shares Lessons from Hot Market
The country lately has struggled to bring its regulatory procedures in line with the rest of the industrialized world, and sweeping health care reforms have benefited 90 percent of the citizenry with health careBy Randy Osborne | BioWorld Today | Friday, June 14, 2013 -
U.S. Biopharma Firms Hit by Cyber Attacks from China
The increased activity against biotechnology firms coincided with the inclusion of pharmaceuticals and health care as strategic growth industries in China's 12th Five Year Plan (FYP), that covers 2011-2015By Shannon Ellis | BioWorld International | Wednesday, June 12, 2013 -
Hitting the BRIC Wall? Report Examines Overseas Challenges
In Russia, Frost & Sullivan said, the regulatory framework for the health care sector is "incoherent," with a registration process that takes up to three years...In India, the private sector provides 70 percent to 75 percent of health care in the country, with the rest provided by government, and the urban/rural divide is high, so that most private health care targets only the tier one citiesBy Randy Osborne | BioWorld Today | Wednesday, June 12, 2013 -
Obesity Drug Competition Set to Begin, Finally
Initially they will have a sales force of 200 reps that will initially target specialists such as endos and cardios," Arena's chief scientific officer Dominic Behan told investors at Deutsche Bank dbAccess Health Care Conference about Eisai's plansBy Brian Orelli | BioWorld Insight | Monday, June 10, 2013 -
U.S. Biopharma Firms Hit by Cyber Attacks from China
The increased activity against biotechnology firms coincided with the inclusion of pharmaceuticals and health care as strategic growth industries in China's 12th Five Year Plan (FYP), that covers 2011-2015By Shannon Ellis | BioWorld Today | Monday, June 10, 2013 -
Big Pharma Must Embrace Disruption or Get Run Over
I am absolutely convinced health care cannot be reformed," Munos saidBy Cormac Sheridan | BioWorld International | Wednesday, June 5, 2013 -
Biotech Flourishing in Flanders; Busy Hub a Standout in Europe
On the health care side, Van Hauwermeiren said the region needs more dedicated local VC funds that can lead investment roundsBy Cormac Sheridan | BioWorld International | Wednesday, June 5, 2013 -
Volume of Industry Deal Making Will Continue its Robust Pace
The new deals, if they are voted through by shareholders, would give Elan commercial footholds in Central and Eastern Europe and in the Middle East, respectively. (See BioWorld Today, May 21, 2013.) These emerging markets are becoming very attractive because of rapidly growing and aging populations in these countries, an increasing prevalence of chronic diseases and a burgeoning middle class requiring quality and accessible health careBio Perspectives | Tuesday, June 4, 2013 -
Epizyme's $77M IPO to Boost Phase I/II Blood Cancers Push
Celsion Corp., of Lawrenceville, N.J., will receive an aggregate of $9.83 million from investors in exchange for common stock in an at-the-market registered direct offering by a dedicated health care fundBy Randy Osborne | BioWorld Today | Monday, June 3, 2013 -
Big Pharma Must Embrace Disruption or Get Run Over
I am absolutely convinced health care cannot be reformed," Munos saidBy Cormac Sheridan | BioWorld Today | Friday, May 31, 2013 -
Biogen's BG-12 Launch Snag: Europe Talks 'Taking Longer'
As part of an SEC filing, and during a slide show at the Deutsche Bank dbAccess Health Care Conference in Boston, Biogen made public the delay of the launch until the second half of this year, saying the firm wants to make "regulatory data protection clearer to all partiesBy Randy Osborne | BioWorld Today | Friday, May 31, 2013 -
Enlivex Harnessing Apoptosis as a New Approach in GVHD
GVHD is a serious disease with no effective cure, added Ophir Shahaf, Hadasit's CEO and chairman of Enlivex, adding that the orphan disease has wider implications for the health care systemBy Marie Powers | BioWorld Today | Thursday, May 30, 2013 -
Volume of Industry Deal Making Will Continue its Robust Pace
The new deals, if they are voted through by shareholders, would give Elan commercial footholds in Central and Eastern Europe and in the Middle East, respectively. (See BioWorld Today, May 21, 2013.) These emerging markets are becoming very attractive because of rapidly growing and aging populations in these countries, an increasing prevalence of chronic diseases and a burgeoning middle class requiring quality and accessible health careBy Peter Winter | BioWorld Today | Thursday, May 30, 2013 -
Taking a Hollywood Cue, Will Congress Remake a Classic?
By Mari Serebrov Washington Editor Revamping Medicare Part D, for some people, would be the health care equivalent of remaking Gone with the WindBio Perspectives | Wednesday, May 29, 2013 -
Clinical Failures Mark End for Agennix, Phytopharm
It now is calling time and has signed heads of agreement for a reverse merger with a health care companyBy Nuala Moran | BioWorld International | Wednesday, May 29, 2013 -
BTG Raises $160M to Fund Nordion, Ekos Acquisitions
The move marks the further maturation of BTG as a medium-sized diversified health care business and a further shift away from its roots as an IP management and out-licensing specialist...The two transactions also could be construed as further evidence that health care investment in Europe is moving away from biotechnology and into lower-risk areasBy Cormac Sheridan | BioWorld International | Wednesday, May 29, 2013 -
Clinical Failures Mark End for Agennix, Phytopharm
It now is calling time and has signed heads of agreement for a reverse merger with a health care companyBy Nuala Moran | BioWorld Today | Wednesday, May 29, 2013 -
Taking a Hollywood Cue, Will Congress Remake a Classic?
Revamping Medicare Part D, for some people, would be the health care equivalent of remaking Gone with the WindBy Mari Serebrov | BioWorld Today | Wednesday, May 29, 2013
Category
Current Filters
- xhealth care
Related Keywords
Categories
- x BioWorld Today (1857)
- x BioWorld International (341)
- x Bio Perspectives (225)
- x BioWorld Insight (187)
- x State of the Industry Report (43)
- x BioWorld Genomics Review (28)
- x BioWorld Snapshots (15)
- x Top 25 Drug Report (9)
- x Recorded (7)
- x Executive Compensation Report (4)
- x Market-Leading Biotech Drugs (3)
- x Biotech Innovations (2)
- x RNAi Report (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.